Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Metformin in Children With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Primary Brain Tumors
Solid Tumors

Interventions: Drug: Vincristine
Drug: Irinotecan
Drug: Temozolomide
Drug: Metformin

First Posted Date: 2012-02-07

Last Posted Date: 2023-01-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 26

Registration Number: NCT01528046

Locations: 🇺🇸
Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 11 locations

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2012-02-01

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT01523977

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
UCSF, San Francisco, California, United States

and more 5 locations

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Not Applicable

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting
Effects of Chemotherapy
Sarcoma
Adverse Effects of Medical Drugs

Interventions: Drug: Fosaprepitant
Drug: Dexamethasone
Drug: 5HT3 receptor antagonist
Drug: Ifosfamide-based chemotherapy (AI)
Drug: Doxorubicin
Drug: Mesna
Drug: Ifosfamide
Drug: Vincristine

First Posted Date: 2011-12-12

Last Posted Date: 2016-04-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01490060

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia
Precursor B-Cell Lymphoblastic Leukemia
Precursor T-Cell Lymphoblastic Leukemia

Interventions: Drug: Decitabine
Drug: Vorinostat
Drug: Vincristine
Drug: Dexamethasone
Drug: Mitoxantrone
Drug: Pegaspargase
Drug: Methotrexate

First Posted Date: 2011-12-01

Last Posted Date: 2020-10-27

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 23

Registration Number: NCT01483690

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺
Sydney Children's Hospital, Sydney, Australia

and more 25 locations

Prospective Study on HIV-related Hodgkin Lymphoma

Phase 2

Conditions: HIV-associated Hodgkin Lymphoma

First Posted Date: 2011-11-09

Last Posted Date: 2011-11-09

Lead Sponsor: Harlachinger Krebshilfe e.V.

Target Recruit Count: 130

Registration Number: NCT01468740

Locations: 🇩🇪
Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany
🇩🇪
Vivantes Auguste Victoria Klinikum, Berlin, Germany
🇩🇪
Ärzteforum Seestrasse, Berlin, Germany

and more 5 locations

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

Not Applicable

Active, not recruiting

Conditions: Pleuropulmonary Blastoma

Interventions: Drug: Vincristine
Drug: Dactinomycin
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Doxorubicin

First Posted Date: 2011-11-03

Last Posted Date: 2024-08-21

Lead Sponsor: Children's Hospitals and Clinics of Minnesota

Target Recruit Count: 156

Registration Number: NCT01464606

Locations: 🇺🇸
Anne K Harris, Minneapolis, Minnesota, United States

A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)

Early Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: vincristine

First Posted Date: 2011-11-02

Last Posted Date: 2015-05-12

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 11

Registration Number: NCT01463852

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Lymphoblastic Lymphoma

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Daunorubicin
Drug: PEG-asparaginase
Drug: Erwinia asparaginase
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Thioguanine
Drug: Clofarabine
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Dexamethasone
Drug: Hydrocortisone
Drug: Etoposide

First Posted Date: 2011-10-13

Last Posted Date: 2022-06-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 23

Registration Number: NCT01451515

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States